IBA Receives FDA Approval of its New Compact Gantry Clearing the Way for Proteus®ONE

July 16, 2014

LOUVAIN-LA-NEUVE, Belgium, July 16, 2014 /PRNewswire/ –

IBA (Ion Beam Applications SA [http://group.iba-worldwide.com/iba-solutions ]), the
world’s leading provider of proton therapy solutions for the treatment of cancer,
announces that it has received Marketing Authorization from the U.S. Food and Drug
Administration (FDA) for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919). IBA
anticipates that this regulatory approval will intensify the international interest in
Proteus(R)ONE*, IBA’s next generation proton therapy compact system.

To view the Multimedia News Release, please click:


Proteus(R)ONE is IBA’s single-room proton therapy system which is smaller, less
expensive, faster to install and encompasses the latest in targeted proton therapy
technologies, including IBA’s Intensity Modulated Proton Therapy (IMPT). IBA created the
Proteus(R)ONE system to allow more patients access to proton therapy globally and has
already sold five Proteus(R)ONE systems in Shreveport, Louisiana (USA), Nice (France),
Taiwan (China) and two in Japan.

* Proteus(R)ONE is the brand name of a new configuration of the Proteus(R) 235.




Source: PR Newswire

comments powered by Disqus